ライフサイエンスコーパス: lung disease

1 monary dysplasia (BPD; also known as chronic lung disease).

2 monia, spinal cord abscess, and interstitial lung disease).

3 ecular mechanisms that underlie inflammatory lung disease.

4 mplicated and patients often develop chronic lung disease.

5 romising therapeutic target for inflammatory lung disease.

6 2-5 years from this progressive interstitial lung disease.

7 ons to CFTR, leads to severe and progressive lung disease.

8 C/TLC in identifying features of obstructive lung disease.

9 consolidations in patients with more severe lung disease.

10 tcomes in hypercapnic patients with advanced lung disease.

11 ociations among air pollution, diabetes, and lung disease.

12 ertension, diabetes, and chronic obstructive lung disease.

13 l therapeutic targets in the treatment of CF lung disease.

14 ther deteriorated in the presence of chronic lung disease.

15 (LBW) are risk factors for neonatal chronic lung disease.

16 SeV- and influenza A virus-induced long-term lung disease.

17 r clinical management of COVID-19 associated lung disease.

18 set, and progression of cystic fibrosis (CF) lung disease.

19 veries that change the natural history of CF lung disease.

20 the periphery to center progression of this lung disease.

21 ive stress, consistent with a key role in CF lung disease.

22 ons, including growth impairment and chronic lung disease.

23 ry vascular dilatation on CE, and absence of lung disease.

24 duce CTSS activity and counter smoke-induced lung disease.

25 f lung US SWE for evaluation of interstitial lung disease.

26 and drastically ameliorated STING-associated lung disease.

27 ay provide opportunities for intervention in lung disease.

28 ers, including among those without prevalent lung disease.

29 t, HIV viral load, or HIV-associated chronic lung disease.

30 pear to influence the development of chronic lung disease.

31 th CF and from 1 patient with non-CF chronic lung disease.

32 sed to hyperoxia who later developed chronic lung disease.

33 (SAVI), affects children and leads to severe lung disease.

34 ution in individuals with underlying chronic lung disease.

35 nary Fibrosis (IPF), a progressive and fatal lung disease.

36 ed health effects, particularly interstitial lung disease.

37 ulmonary dysplasia (BPD), a neonatal chronic lung disease.

38 n important pathogenic component of fibrotic lung disease.

39 and study participants with any interstitial lung disease.

40 nal repair play a role in the development of lung disease.

41 tic target against premalignancy and chronic lung disease.

42 ontribute to dysregulated host defense in CF lung disease.

43 putum samples of individuals with underlying lung disease.

44 infections and the progression of structural lung disease.

45 cal thromboinflammatory effector cells in CF lung disease.

46 n) from 17 patients with no, mild, or severe lung disease.

47 ies and findings suspicious for interstitial lung disease.

48 ractive target for the treatment of fibrotic lung diseases.

49 tic targets in the management of obstructive lung diseases.

50 goes on to drive development of most chronic lung diseases.

51 n is essential for recovery from devastating lung diseases.

52 in the diagnosis and treatment of a range of lung diseases.

53 ic tools to treat patients with a variety of lung diseases.

54 nditions such as hypertension, diabetes, and lung diseases.

55 e central to the pathogenesis of a number of lung diseases.

56 airways and lung samples from patients with lung diseases.

57 gs, is a component of many chronic and acute lung diseases.

58 owing the in vitro modeling of a plethora of lung diseases.

59 ful in preventing alloimmune-driven fibrotic lung diseases.

60 h symptoms that overlap infectious and other lung diseases.

61 hologies are prominent in neonatal and adult lung diseases.

62 harmacologic target for inflammation-related lung diseases.

63 e pathogenesis of allergy, asthma, and other lung diseases.

64 ding diagnosis and prognosis in interstitial lung diseases.

65 stic fibrosis and other pre-existing chronic lung diseases.

66 alidate this approach across a wide range of lung diseases.

67 isms that mediate distinct chronic postviral lung diseases.

68 and sepsis and can trigger exacerbations of lung diseases.

69 ncreased susceptibility to acute and chronic lung diseases.

70 lopment of therapeutics to treat obstructive lung diseases.

71 athophysiology of emphysema and inflammatory lung diseases.

72 ty in patients with severe acute and chronic lung diseases.

73 gy could inform our understanding of complex lung diseases.

74 ase (COPD) and asthma remain prevalent human lung diseases.

75 l facilitate interpretation of risk loci for lung diseases.

76 D (Global Initiative for Chronic Obstructive Lung Disease) 2020 Report aims to provide a nonbiased re

77 117 acute hospitalizations with obstructive lung disease, 227 acute hospitalizations with pneumonia,

78 ease (11.8% versus 6.0%, p = 0.006), chronic lung disease (28.0% versus 19.3%, p = 0.007), diabetes (

79 [SD], 62.4 years +/- 12.9) with interstitial lung disease and 30 healthy subjects (women, 16; men, 14

80 End-stage lung disease and advanced cardiac conditions are frequen

81 were undergoing evaluation for interstitial lung disease and had had samples obtained by clinically

82 o distinct stages of progression of COVID-19 lung disease and highlights the need for peripheral bloo

83 ttee of experts in the field of interstitial lung disease and HP using the GRADE (Grading of Recommen

84 tabolism have been described during fibrotic lung disease and in murine models of lung fibrosis.

85 ons adds to our evolving understanding of CF lung disease and may help guide antibiotic therapies tar

86 ivacaftor was associated with improvement in lung disease and nutritional status in patients who tole

87 he nivolumab group (one each of interstitial lung disease and pneumonitis) and three in the chemother

88 escribe 2 patients presenting with end-stage lung disease and significant aortic stenosis who were su

89 ction and can be used to define the basis of lung disease and test immune and antiviral-based counter

90 jective information used in the diagnosis of lung diseases and monitoring lung health.

91 with minimal side effects a wide variety of lung diseases and possibly other acute respiratory syndr

92 acute myocardial infarction and interstitial lung disease) and one (<1%) in the placebo group (arrhyt

93 lactate dehydrogenase level, distribution of lung disease, and chest radiography score at hospital pr

94 obstructive pulmonary disease, interstitial lung disease, and coronary artery disease.

95 Older age, chronic lung disease, and hypertension were associated with seve

96 en groups by age (mean, ~79), heart failure, lung disease, and influenza and pneumococcal vaccine upt

97 ry fibrosis (IPF) is a progressive and fatal lung disease, and its molecular pathogenesis remains poo

98 minal pain, colitis, hepatitis, interstitial lung disease, and jaundice, and grade 4 cholestasis, and

99 ng, cyanotic heart disease, active perinatal lung disease, and preparation or recovery from a cardiac

100 153S mice that lack adaptive immunity had no lung disease, and T-cell receptor beta chain (Tcrb)(-/-)

101 failure, stroke, asthma, chronic obstructive lung disease, and type 2 diabetes mellitus.

102 e [aOR 3.2, 95%CI 1.4-7.0, p=0.004], chronic lung disease [aOR 2.5, 95%CI 1.2-5.2, p=0.018], obesity

103 that macrophage contributions to CF-related lung disease are primarily shaped by their environment.

104 Lung diseases are a leading cause of mortality worldwide

105 acterized animal models of postviral chronic lung diseases are necessary to study the underlying mech

106 ar epithelial turnover observed with chronic lung diseases are unknown.

107 rmalities, such as emphysema and restrictive lung diseases, are frequently observed in patients with

108 in large animals to enable modeling of human lung disease as well as cell-based therapeutic intervent

109 e pulmonary disease (COPD) is a debilitating lung disease associated with cigarette smoking.

110 Allergic asthma is a chronic inflammatory lung disease associated with increased cytokine secretio

111 severe bronchopulmonary dysplasia, a chronic lung disease associated with preterm birth, which is cha

112 -hospital mortality in fibrotic interstitial lung disease-associated mechanical ventilation when view

113 Among participants without prevalent lung disease, associations were attenuated but were cons

114 All 14 patients showed first signs of lung disease at a median onset of 1.5 years of age.

115 used to successfully investigate airway and lung diseases at single-cell resolution.

116 ith pulmonary vascular pathology and chronic lung diseases, but it remains unclear whether endothelia

117 alled the Pi*ZZ genotype, causes a liver and lung disease called alpha-1 antitrypsin deficiency.

118 airways of smokers and patients with chronic lung disease, can cause pneumonia and sepsis and can tri

119 tigation of pathologies such as interstitial lung disease, cancer and coronavirus disease 2019 (COVID

120 2018) and the Canadian Cohort of Obstructive Lung Disease (CanCOLD), which involved 1272 participants

121 of diabetes, hypertension, stroke, cancers, lung diseases, cardiovascular diseases, and cognitive im

122 higher prevalence of chronic kidney, liver, lung diseases, cardiovascular diseases, type 2 diabetes,

123 In this study, we cross-analyzed chronic lung disease caused by infection with Sendai virus (SeV)

124 is only reserved for patients with advanced lung disease caused by severe AAT deficiency.

125 ystem disorder, but progressive inflammatory lung disease causes the greatest burden of morbidity and

126 iopathic pulmonary fibrosis (IPF) are severe lung diseases causing irreversible lung damage and prema

127 ) conducted in 39 UK specialist interstitial lung disease centers between April 2015 (first patient v

128 t 65 pulmonary hypertension and interstitial lung disease centres in 19 countries to evaluate the eff

129 Interstitial lung disease characteristics, demographics, and ventilat

130 pulmonary hypertension (PH) is an infantile lung disease characterized by aberrant angiogenesis and

131 he major cause of morbidity and mortality is lung disease characterized by inflammation and infection

132 (IPF) is a chronic progressive interstitial lung disease characterized by patchy scarring of the dis

133 ronchopulmonary dysplasia is a heterogeneous lung disease characterized by regions of cysts and fibro

134 pathic pulmonary fibrosis (IPF) is a complex lung disease characterized by scarring of the lung that

135 Childhood interstitial lung disease (chILD) comprises a spectrum of rare diffus

136 Children's interstitial and diffuse lung disease (chILD) is a rare heterogenous group of con

137 ren with children's interstitial and diffuse lung disease (chILD) to improve diagnostic approaches, i

138 tly older; more frequently presented chronic lung disease, chronic heart failure, prior endocarditis,

139 he Global Initiative for Chronic Obstructive Lung Disease classification system (P = .0015), more fre

140 In those without known chronic lung disease (CLD) (HR, 3.09; P = .024) and those withou

141 Chronic lung disease (CLD) has been reported among African child

142 Chronic lung disease (CLD) is a common co-morbidity for HIV-posi

143 osis and in human subjects with interstitial lung disease compared to that in control healthy subject

144 17 Global Initiative for Chronic Obstructive Lung Disease criteria.

145 ations into the specific mechanisms by which lung disease develops in RA will be crucial for the deve

146 ue for sampling lung tissue for interstitial lung disease diagnosis.

147 the clinical utility of TBLC in interstitial lung disease diagnostic algorithms.

148 of people worldwide with incurable end-stage lung disease die because of inadequate treatment options

149 oleiomyomatosis (LAM) is a rare fatal cystic lung disease due to bi-allelic inactivating mutations in

150 crophage activation, and the pathogenesis of lung disease due to CS exposure.

151 We confirmed the induction of lung disease enhancement by vaccinations with low antige

152 gainst RSV infection but also induced severe lung disease enhancement in vaccinated children.

153 participants with any grade of interstitial lung disease (F1-F3).

154 ies cell types that are directly affected by lung disease genes and respiratory viruses.

155 Granulomatous and lymphocytic interstitial lung disease (GLILD) is a life-threatening complication

156 en Global Initiative for Chronic Obstructive Lung Disease (GOLD) 1 and GOLD 4 COPD was reduced by 13.

157 98 Global Initiative for Chronic Obstructive Lung Disease (GOLD) 1-4 patients and 3,479 controls from

158 ng Global initiative for chronic Obstructive Lung Disease (GOLD) criteria.

159 by Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage (GOLD 0, no COPD; GOLD 1, mild

160 city of 81% for differentiating interstitial lung disease grades F0-F2 from F3.

161 r to suboptimal clinical outcomes in various lung disease groups.

162 extensive pulmonary fibrosis or restrictive lung disease has occurred.

163 tem, where circadian rhythms in inflammatory lung disease have been appreciated since ancient times.

164 e interval, 3.39-12.2) for acute obstructive lung disease hospitalizations, 2.03 (1.43-2.88) for acut

165 During the progression of CF lung disease, however, the emergence of multidrug antimi

166 D (Global Initiative for Chronic Obstructive Lung Disease II-IV) who were carefully characterized (in

167 ine progression toward clinical interstitial lung disease (ILD) among subjects in a longitudinal coho

168 ) is prevalent in patients with interstitial lung disease (ILD) and may reflect immunologic activatio

169 as the current gold standard-in interstitial lung disease (ILD) cases requiring histology remains con

170 ase (COVID-19) on patients with interstitial lung disease (ILD) has not been established.Objectives:

171 Interstitial lung disease (ILD) is fast approaching chronic obstructi

172 identification of more advanced Interstitial Lung Disease (ILD) patterns, few have tackled ILA, which

173 Rationale: Interstitial lung disease (ILD) represents a major challenge in syste

174 nary disease (COPD), asthma and interstitial lung disease (ILD), and individual cardiovascular diseas

175 F) are at an increased risk for interstitial lung disease (ILD), the risk among relatives of sporadic

176 re available for unclassifiable interstitial lung disease (ILD), which is characterised by progressiv

177 rtality, even in the absence of Interstitial Lung Disease (ILD).

178 25% to 30% develop progressive interstitial lung disease (ILD).

179 ents as pulmonary hemorrhage or interstitial lung disease (ILD).

180 ve pulmonary disease (COPD) and interstitial lung disease (ILD).Methods: The multidisciplinary panel

181 fections (EAR, 10.6; SMR, 3.9), interstitial lung disease (ILD; EAR, 9.7; SMR, 22.1), and adverse eve

182 round Longitudinal follow-up of interstitial lung diseases (ILDs) at CT mainly relies on the evaluati

183 ung diseases such as asthma and interstitial lung diseases (ILDs), including idiopathic pulmonary fib

184 Lung cancer and chronic lung diseases impose major disease burdens worldwide and

185 sk factors, and potential pathophysiology of lung disease in individuals with established RA.

186 cial component in the treatment of end-stage lung disease in infants.

187 y predispose individuals to be vulnerable to lung disease in later life.

188 e immunodeficiency, leading to virus-induced lung disease in mice.

189 N153S relies primarily on T cells to promote lung disease in mice.

190 he hypothesis that impaired lung function or lung disease in midlife is associated with greater risk

191 ver, a single dose conferred protection from lung disease in most of the vaccinated hamsters within a

192 important contributors to the development of lung disease in patients with RA.

193 gic and functional worsening of interstitial lung disease in patients with systemic sclerosis.

194 of this study was to expand knowledge about lung disease in STAT3-HIES.

195 Lung disease in STING N153S mice developed independently

196 Spontaneous lung disease in STING N153S mice develops independently

197 splant candidacy for patients with end-stage lung disease in the setting of severe aortic stenosis, l

198 could herald the development of significant lung disease in these susceptible individuals.

199 s a fatal and incurable form of interstitial lung disease in which persistent injury results in scar

200 ssociated with the progression of structural lung disease in young children with CF.

201 ociations between Aspergillus infections and lung disease in young children with CF.Methods: Longitud

202 terium, is increasingly prevalent in chronic lung disease, including cystic fibrosis, and infections

203 the two pivotal features of cystic fibrosis lung disease, inflammation and infection, and thus repre

204 These data suggest chronic lung disease influences the microbiota of sputum in pati

205 erm birth, congenital heart disease, chronic lung disease, intensive care unit admission, and ventila

206 lung function in patients with interstitial lung disease is accompanied by epithelial remodeling and

207 Cystic fibrosis (CF) lung disease is characterized by an inflammatory respons

208 CF lung disease is driven by innate immune dysfunction and

209 receptors in mice helps explain why COVID-19 lung disease is greater in the elderly and people with p

210 The severity of COVID-19 lung disease is higher in the elderly and people with pr

211 Lung disease is independently associated with cardiovasc

212 (IPF), a fatal and irreversible interstitial lung disease, is predicted by the circulating blood conc

213 Underlying cardiovascular disease, lung disease, kidney disease, diabetes, immunosuppressio

214 fibrosis-related diabetes (CFRD) worsens CF lung disease leading to early mortality.

215 vascular remodeling (PVR) are common in many lung diseases leading to right ventricular dysfunction a

216 ASM with the pathogenesis of T(H) 1-directed lung diseases like cystic fibrosis and acute lung injury

217 for acquisition of TCD included pre-existing lung diseases, lower GI endoscopy and antibiotics.

218 living with HIV have high burdens of chronic lung disease, lung cancers, and pulmonary infections des

219 dverse events were worsening of interstitial lung disease (main study: six [8%] of 73 in the riocigua

220 cGAS-STING pathway over-activation can drive lung disease, making this pathway a promising therapeuti

221 analyze the association of FSTL-1 SNPs with lung disease.Methods: FSTL-1 hypomorphic (FSTL-1 Hypo) m

222 of immune function and the development of CF lung disease.Methods: We performed single-cell RNA seque

223 related phenotypes in a cystic fibrosis-like lung disease model (i.e., Scnn1b-Tg-positive [Tg+]) mous

224 fidence interval, 1.14-2.19) and obstructive lung disease (multivariable-adjusted odds ratio, 1.33; 9

225 in many situations including high altitude, lung disease, obstructive sleep apnea, and age-related C

226 IA among recipients with underlying chronic lung diseases (odds ratio [OR] = 7.26; 95% confidence in

227 pulmonary adenocarcinoma (OPA), a neoplastic lung disease of sheep.

228 osis (IPF) is a rare and devastating chronic lung disease of unknown etiology.

229 a progressive and heterogeneous interstitial lung disease of unknown origin with a low survival rate.

230 The primary outcome was the severity of lung disease on admission chest radiographs, measured by

231 eristics associated with escalation included lung disease, ongoing angina, and periprocedural major a

232 rs that can distinguish active TB from other lung diseases (OPD), and that could be further evaluated

233 tions, regardless of diagnosis (interstitial lung disease or chronic obstructive pulmonary disease).

234 5; 95% CI = 1.24-8.03), and comorbid chronic lung disease (OR = 3.87; 95% CI = 1.52-9.83).

235 1.3; 95% CI: 1.1, 1.6, P = .01), and chronic lung disease (OR, 1.3; 95% CI: 1.0, 1.6; P = .02).

236 Patients with chronic lung disease (other than asthma) were excluded.

237 Affected patients developed chronic lung disease over time (47% after 40 years of follow-up)

238 t, dehydration, hepatotoxicity, interstitial lung disease, pancytopenia, and sepsis [n=1 each]), and

239 causative agent of the devastating COVID-19 lung disease pandemic.

240 The potential impact on chronic lung disease pathogenesis needs further investigation.

241 the lung, sparking exploration of clocks in lung disease pathophysiology.

242 s of a large cohort of fibrotic interstitial lung disease patients from the perspective of an acute r

243 of 10 patients (1.2% of the 760 restrictive lung disease patients transplanted in the same time peri

244 gnificant mortality in fibrotic interstitial lung disease patients undergoing mechanical ventilation.

245 infection, none have fully recapitulated the lung disease phenotypes seen in humans who have been hos

246 estigators reported 20 cases of interstitial lung disease, pneumonitis, or organising pneumonia, incl

247 d an effect modification whereby obstructive lung disease prevalence among persons with limited smoki

248 The unadjusted obstructive lung disease prevalence was similar in HIV-infected (23.

249 Baseline comorbidities (diabetes, chronic lung disease, previous acute HF) and echocardiographic f

250 dmission included diabetes mellitus, chronic lung disease, previous acute HF, grade III or IV aortic

251 rence in change in King's Brief Interstitial Lung Disease Questionnaire (K-BILD) score at 24 weeks.Me

252 Questionnaire, and King's Brief Interstitial Lung Disease questionnaire scores).

253 ighly active antiretroviral therapy (HAART), lung disease remains common in human immunodeficiency vi

254 They suffered from restrictive lung disease requiring noninvasive mechanical ventilatio

255 ity and findings suspicious for interstitial lung disease, respectively.

256 pleted a questionnaire regarding obstructive lung diseases, respiratory symptoms, potential risk fact

257 bone marrow chimeric mice were assessed for lung disease severity and survival.

258 thelial cells in adult mice produces chronic lung disease sharing key features with IPF including pro

259 e and its risk factors, diabetes, underlying lung disease, smoking, immunosuppressed condition, and b

260 and former Global Initiative for Obstructive Lung Disease stage 0 smokers predicted structural and ph

261 defined as Global Initiative for Obstructive Lung Disease stage 0).

262 in Global Initiative for Chronic Obstructive Lung Disease stage 4 versus stage 1 COPD (P < 0.0001).

263 to Global Initiative for Chronic Obstructive Lung Disease stage higher than 1 (odds ratio = 1.96 [95%

264 17 Global Initiative for Chronic Obstructive Lung Disease stage II subjects with COPD and as controls

265 th Global Initiative for Chronic Obstructive Lung Disease stage II-IV COPD and persistent symptoms an

266 as Global Initiative for Chronic Obstructive Lung Disease stage II-IV were enrolled.

267 on Global Initiative for Chronic Obstructive Lung Disease stage IV COPD lungs with TLOs.Measurements

268 been implicated in the pathology of chronic lung diseases such as asthma and interstitial lung disea

269 mucus biology and improve the management of lung diseases such as asthma, cystic fibrosis, and chron

270 ity, especially in patients with preexisting lung diseases such as asthma.

271 ssociated protease with elevated activity in lung diseases such as bacterial infection and alpha-1 an

272 osis and inflammation that underlies chronic lung diseases such as idiopathic pulmonary fibrosis (IPF

273 ulation and has been associated with several lung diseases, such as asthma, pulmonary fibrosis, and l

274 variables included sex, chronic obstructive lung disease, symptom duration, neutrophil count, C-reac

275 Pneumonia is a lung disease that can cause respiratory failure and hypo

276 In concert, the chronic lung disease that develops after Sendai virus infection

277 e pulmonary disease (COPD) is a debilitating lung disease that is currently the third leading cause o

278 nts with COPA syndrome develop arthritis and lung disease that presents as pulmonary hemorrhage or in

279 IPF) are two pathologically distinct chronic lung diseases that are associated with cigarette smoking

280 c dysfunction that may contribute to chronic lung diseases that arise in association with TLO formati

281 prevent deregulated tissue cell activity in lung diseases that involve fibrosis and remodeling.

282 sponse to AA protected against S. pneumoniae lung disease, the IL-6 deficiency abrogated the protecti

283 s might be valuable in patients with certain lung diseases, the goal was to find out if ABC-like cell

284 ding and management of lung inflammation and lung disease throughout the natural history of RA.

285 bstructive pulmonary disease or interstitial lung disease transplant recipients is associated with al

286 At postnatal days 12 and 18, mild lung disease was evident by histopathologic analysis tog

287 Severity of interstitial lung disease was graded as none (healthy lung [F0]), mil

288 currence of radiation-associated cardiac and lung disease was rare and not influenced by the fraction

289 hat coronary artery disease, but not chronic lung disease, was associated with death among hospitaliz

290 Participants with prevalent clinical lung disease were excluded.

291 Patients with lung disease were less likely to receive coronary revasc

292 Emphysema and chronic obstructive lung disease were previously identified as major risk fa

293 Lung diseases were also assessed as dichotomous variable

294 nction decline and susceptibility to chronic lung diseases, which are the third leading cause of deat

295 distress syndrome (ARDS) is an inflammatory lung disease with a high morbidity and mortality rate, f

296 fibrosis (IPF) is a progressive interstitial lung disease with a median survival of 3 years after dia

297 ic pulmonary fibrosis (IPF) is a progressive lung disease with a poor prognosis.

298 nary fibrosis (IPF) is a chronic progressive lung disease with limited therapeutic options and poor p

299 mune response leading to long-term postviral lung diseases with features of asthma and related progre

300 Research on acute and chronic lung diseases would greatly benefit from reproducible av